Recent News

• 01.02.2026 - Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
• 04.30.2025 - Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
• 04.14.2025 - Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
• 02.27.2025 - Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
• 02.20.2025 - Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
• 01.29.2025 - Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
• 11.26.2024 - Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
• 11.13.2024 - Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
• 11.07.2024 - Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• 11.07.2024 - Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Recent Filings